Based in London, Claret Capital is one of Europe's leading private equity firms making investments and providing growth debt to European tech and life-science businesses.
The Abivax financing includes up to €75 million from Claret European Growth Capital Fund III and Kreos Capital, and up to €75 million from a fund advised by Heights Capital Management, Inc.
Specialising in biotechnology, this financing, organised in several tranches, will enable Abivax to continue developing its lead drug, obefazimod, a treatment for ulcerative colitis and other chronic inflammatory conditions.
Reed Smith acted alongside Claret Capital Partners – with partner Baptiste Gelpi and associate Chuanyu Fan on the financing side, and partner Guilain Hippolyte and associates Marine Deyrolle and Marco Hazan on the corporate side.
Abivax was advised by Dechert.